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ApoA-I mimetics are short synthetic peptides that contain an amphipathic a-helix and stimulate
cholesterol efﬂux by the ABCA1 transporter in a detergent-like extraction mechanism. We investigated
the use of amphipathic peptides with a polypro helix for stimulating cholesterol efﬂux by ABCA1. Polypro
peptides were synthesized with modiﬁed prolines, containing either a hydrophobic phenyl group (Prop)
or a polar N-acetylgalactosamine (Prog) attached to the pyrrolidine ring and were designated as either
PP-2, 3, 4, or 5, depending on the number of 3 amino acid repeat units (Prop-Prog-Prop). Based on mo-
lecular modeling, these peptides were predicted to be relatively rigid and to bind to a phospholipid
bilayer. By CD spectroscopy, PP peptides formed a Type-II polypro helix in an aqueous solution. PP-2 was
inactive in promoting cholesterol efﬂux, but peptides with more than 2 repeat units were active. PP-4
showed a similar Vmax as a much longer amphipathic a-helical peptide, containing 37 amino acids,
but had a Km that was approximately 20-fold lower. PP peptides were speciﬁc in that they did not
stimulate cholesterol efﬂux from cells not expressing ABCA1 and were also non-cytotoxic. Addition of PP-
3, 4 and 5 to serum promoted the formation of smaller size HDL species (7 nM) and increased its capacity
for ABCA1-dependent cholesterol efﬂux by approximately 20e35% (p < 0.05). Because of their relatively
small size and increased potency, amphipathic peptides with a polypro helix may represent an alter-
native structural motif for the development of apoA-I mimetic peptides.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
There is great interest in the development of synthetic High
Density Lipoprotein (HDL) particles as a potential therapy for car-
diovascular diseases [1e3]. Either full length ApoA-I [4], which
contains a tandem array of amphipathic a-helices, or short ApoA-I
mimetic peptides [5,6], are used as the protein component of
synthetic HDL particles. ApoA-I mimetic peptides are typically
designed to form an amphipathic a-helix, so that one side of the
helix contains hydrophobic amino acids and faces the lipid core of
HDL, whereas the other side contains amino acids with hydrophilic
side chains that face toward the aqueous environment. It has been
shown in numerous studies that apoA-I mimetic peptides, like theorter A1; BHK, baby hamster
ow density lipoproteins; PEG,
th, Bldg. 10, Room 8N-218, 10
dov).
r Inc. This is an open access articlfull-length apoA-I protein, can efﬂux excess cellular cholesterol by
the ABCA1 transporter in a detergent-like extraction process [7,8].
These peptides reduce atherosclerosis in various animal models
[5,6,9], and also show beneﬁt in several other disease models,
particularly inﬂammatory diseases [10].
Peptides that are enriched in proline can also form helices,
namely type I and type II polypro helices [11]. The polypro type II
helix, with its peptide bond in the trans-conﬁguration, is more
common than the type I polypro helix and is structurally quite
different than the a-helix. It forms a left-handed helix with 3 amino
acids per turn and has an overall shape of a triangular prism, with a
rise per residue of approximately 3.1 Å. In contrast, the a-helix is
right-handed, contains 3.6 amino acids per turn and has a rise per
residue of only 1.5 Å, which means that for the same number of
amino acids a polypro type II helix will be about twice as long an a-
helix. Even though the polypro type II helix has no backbone
hydrogen bonds to stabilize its secondary structure like the a-helix,
it is, nevertheless, very rigid. In fact, polypro peptides are used as
“molecular rulers” in FRET type analysis [12]. The reason that pol-
ypro peptides are so rigid is because the pyrrolidine side chain ringe under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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peptide backbone, which limits the permissible dihedral angles of
the peptide bond to a conformation that favors helix formation [11].
As a consequence, polypro helices can be much shorter than a-
helices, because they do not require stabilization by backbone
hydrogen bonding. A cross section of polypro peptides shows
almost a perfect 3-fold symmetry, because their side chains are
arranged every 120 unlike a-helices, which instead occur about
every 100. Polypro helices, containing modiﬁed prolines with
attached side chain groups [13], can potentially form amphipathic
helices much longer than the typical limit of 18e20 residues for a-
helices, because the relative orientation of their side chains will be
maintained throughout the length of the helix.
In this study, we used modiﬁed prolines to synthesize novel
amphipathic polypro peptides. To form the hydrophobic base of the
triangular prism shape of the polypro peptide, we used two
modiﬁed proline residues (Prop), containing a hydrophobic phenyl
group covalently attached to the pyrrolidine ring. The hydrophilic
“apex” of the peptide was designed to contain a modiﬁed proline
residue with a polar N-Acetylgalactosamine (GalNAc) sugar
attached to its side chain (Prog). We hypothesized that short pep-
tides based on a repeating unit of these 3 modiﬁed amino acids
(Prop-Prog-Prop) would form polypro helices and be effective in
promoting cholesterol efﬂux by the ABCA1 transporter, because of
their relative rigidity and amphipathic structure.2. Materials and methods
2.1. Peptide synthesis and modiﬁcation
Peptides were synthesized by a solid-phase procedure, using
FMOCeprotected amino acids on a Biosearch 9600 peptide syn-
thesizer (Bioresearch, Japan), as described in Fig. 1. Trans-Fmoc-4-
azido-L-proline (Proa) from IRIS BIOTECH, GMBH (Germany) and
Fmoc-(2S, 4R)-4-benzyl-pyrrolidine-2-carboxylic acid (Prop) from
AnaSpec, Inc. (Fremont, CA) were used to form polypro peptides
with a variable number of the (Prop-Proa-Prop)n repeat units and
were abbreviated as PP-n, with n designating the number of repeat
units (Fig. 1A). After cleavage from resin with triﬂuoroacetic acid,
the peptides were lyophilized and a-GalNAc was attached via a PEG
trimer linkage to the azido group of Proa residues by the following
click chemistry reaction: 3 mM peptides (PP-2, PP-3, PP-4, PP-5)
and a-GalNAc-TEG-Alkyne (IRIS BIOTECH, GMBH) at a concentra-
tion of 9 mM, 13.5 mM, 18 mM and 22.5 mM respectively (alkyne/
azide molar ratio was 1.5) were solubilized in dimethylformamide
(SigmaeAldrich, Saint-Louis, MO) and then added to the reaction
mixture of 70% dimethylformamide with 4.5 mM CuSO4 and 9 mM
sodium ascorbate. The reaction was heated in a microwave (CEM
Corp., USA) at 50 C with 25 W power for 2 h. The reaction was
monitored by taking 2ul of the ﬁnal peptide product and placing it
on an Anchorchip target and allowed to dry at 45 C. It was overlaid
with 2ul of a saturated solution of a-cyano-4-hydroxycinnamic acid
in 50% ACN, 2.5% TFA and analyzed in a MALDI AutoFlex III (Bruker
Daltonic, Billerica, MA), using the linear detector in positive mode
between 2000 and 20,000 Da.2.2. Circular Dichroism (CD) spectroscopy
Peptides at a concentration of 0.1 mg/ml in 0.015 M sodium
phosphate buffer, pH 7.4, were loaded into a quartz cuvette
(d ¼ 0.2 cm path length) and the CD spectra from 185 to 240 nm
were recorded on a Jasco J715 spectropolarimeter at 24 C. The
polypro type II helix was identiﬁed by its characteristic CD spec-
trum, which has a nadir at 198 nm and a peak at 218 nm [14].2.3. In vitro cholesterol efﬂux assay
Cholesterol efﬂux studies were performed as previously
described [6]. Brieﬂy, BHK-mock (control) and ABCA1-transfected
BHK cells were incubated with 1 mCi/ml of [3H]-cholesterol in
DMEM. After 24 h, the media was replaced with DMEM containing
the peptides or PBS vehicle control. After 18 h of incubation,
radioactive counts in media and cell lysates were measured by
liquid scintillation counting on a Perkin Elmer MicroBeta 1450
scintillation counter. Results are expressed as the percentage of
total counts appearing in the media.
Cholesterol efﬂux to LDL-depleted plasma spiked with the pol-
ypro peptides was performed as described above but only with 4 h
of incubation. LDL-depleted plasma was prepared by PEG precipi-
tation [15] and tested at a ﬁnal concentration of 1% (vol:vol).
2.4. Plasma HDL remodeling
Remodeling of plasma HDL was assessed by adding 50 uL of
5 mg/ml of peptides or 50 uL of PBS as a vehicle control to 450 uL of
pooled human plasma. Samples were incubated at 37 C for 1 h in
an orbital shaker at 300 rpm. HDL subclasses were separated by size
by native PAGE, using 10-well Tris-Borate-EDTA gradient (3e25%)
acrylamide gels (Jule, Inc.,USA) [16]. Proteins were transferred onto
PVDF membrane and incubated overnight with anti-human apoA-
I-HRP conjugate antibody (Meridian Life Science,USA). Images were
acquired on an Alpha Innotech Chemi Imager 5500.
2.5. Molecular dynamic modeling
PP-5 structure was modelled using UCSF Chimera software
(v.1.10.2, Regents of the University of California, USA) [17], with 4, j
torsional angles of 75, 145 for the peptide's secondary structure
[11]. The peptide was relaxed in an aqueous environment by all
atom simulation, using Desmond Molecular Dynamics System
(version 4.3, DE Shaw Research, USA, 2015) [18]. The ﬁnalized
structure was oriented against a POPC lipid bilayer and energy
minimization was performed for 25 nanosec, using the same soft-
ware application. The results were visualized using Maestro soft-
ware (v.10.2.011, Schr€odinger, New York, NY, 2015.) Initial GSG-10
peptide structure was modeled as an a-helix (4, j ¼ 60, 45),
using UCSF Chimera software followed by relaxation in an aqueous
environment as described above.
3. Results
3.1. Molecular dynamic modeling of the polyproline peptides
Before peptide synthesis, we ﬁrst performedmolecular dynamic
modeling to predict the possible behavior of the polypro peptide
PP-5, containing 5 trimeric repeat units (Prop-Prog-Prop)5 in an
aqueous solvent and when associated with a phospholipid bilayer.
A structural model for one turn of the PP-5 peptide is shown in
Fig. 2A. Each side chain radiates off the central peptide backbone at
120, so that the two hydrophobic phenyl rings attached to the
modiﬁed Prop residues form a hydrophobic base and the polar Pro
residue with the attached polar GalNac side chain (Prog) is at the
top. The stability of a hypothetical PP-5 peptide forced into a pol-
ypro Type-II conﬁguration was compared to a theoretical GSG-10
peptide, containing 10 repeat units of Gly-Ser-Gly, which were
initially arranged in an a-helical conformation. The distance be-
tween a-carbon atoms in the ﬁrst and the last peptide bonds were
plotted against the simulation time (Fig. 2B). The starting distance
for a “perfect” helix for both peptides was calculated to be
approximately 42 Å. After a 12 nanosec stabilization period, the PP-
Fig. 1. Synthesis and post synthetic modiﬁcation of polypro peptides. A. Each peptide repeat unit contained three amino (two Proline-phenyls and one Azido-Proline). After peptide
synthesis, GalNAc-PEG-alkyne molecules were attached to Azido-Prolines by a “click chemistry” reaction (highlighted by dashed square). B. MALDI-TOF MS spectrum of PP-15
peptide before (top panel) and after (bottom panel) addition of GalNAc-PEG. C. CD spectra of polypro peptides. The relative proportion of polypro type II helical content can be
observed by peak heights at approximately 198 and 218 nM.
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variation throughout the simulation, whereas the average distance
for the GSG-10 peptide was only 8.8 Å, with a 29.7% coefﬁcient of
variation. These data are consistent with the PP-5 peptide largely
maintaining its initial polypro type-II helical structure, whereas the
GSG-10 peptide collapsed over time into a random coil.
When bound to a phospholipid bilayer, the PP-5 peptide was
predicted to peripherally associate with the membrane, with most
of the hydrophobic phenyl groups of the modiﬁed Prop residues
inserting into the lipid bilayer (Fig. 2C). The position of the polar
GalNAc residues were more variable but usually faced toward the
aqueous water phase. Based on these simulations, the PP-5 peptide
appeared to potentially have the proper structural features for
promoting cholesterol efﬂux by the ABCA1 transporter [8].3.2. Polyproline peptides biophysical properties
A total of 4 polypro peptides (PP-2, PP-3, PP-4 and PP-5), con-
taining 2, 3, 4 and 5 of the trimer repeat unit (Prop-Prog-Prop), were
synthesized as described in Fig. 1A. The complete synthesis of each
peptide and the attachment of GalNAc groups were conﬁrmed by
determining the ﬁnal MW of the peptides by MALDI-TOF analysis
(Fig. 1B). The secondary structure of the synthesized peptides in
aqueous solution was determined by CD spectroscopy (Fig. 1C).
Based on their CD spectra, all of the peptides were found to form
polypro Type-II helices, and the degree of helicity increased with
peptide length.3.3. Polyproline peptides promote cholesterol efﬂux
We next tested the ability of the polypro peptides to stimulate
cholesterol efﬂux from BHK cells transfected with the ABCA1
transporter (Fig. 3). As a comparator, we also tested the 5A peptide
[19]. 5A is a bi-helical peptide of 37 amino acids. It contains two
amphipathic a-helices linked by proline and has been shown to
promote ABCA1-dependent cholesterol efﬂux and reduce athero-
sclerosis in mice [6]. The PP-2 peptide was inactive, but the PP-3
peptide was equivalent or better than the much longer 5A pep-
tide in stimulating cholesterol efﬂux. PP-4 was the most potent
peptide. It had a similar apparent Vmax as the 5A peptide for
cholesterol efﬂux but its apparent Km was approximately 20-fold
lower than the 5A peptide. Interestingly, the longer PP-5 peptide
was less effective than the PP-4 peptide. None of the peptides show
non-speciﬁc cholesterol efﬂux when tested in BHK cells not
expressing the ABCA1 transporter (Supplement Fig. 1) nor did they
appear to be cytotoxic, as measured by erythrocyte hemolysis
(Supplement Fig. 2).
3.4. Polyproline peptides increase plasma cholesterol efﬂux capacity
We next tested the effect of the polypro peptides on HDL sub-
class distribution and on ex vivo plasma cholesterol efﬂux (Fig. 4). It
has been previously shown that 5A and other apoA-I mimetic
peptides can remodel existing plasma HDL particles in serum by
causing the displacement of apoA-I and the formation of small pre-
b HDL size particles [5,9]. The generation of pre-b HDL in serum
leads to an increase in ABCA1-dependent cholesterol efﬂux and has
been used as a marker for synthetic HDL function [4]. Like the 5A
Fig. 2. Molecular Dynamic modeling of the peptides. A. Prop-Prog-Prop subunit model. Phenyl rings on Prop are highlighted in red and GalNac-PEG-alkyne attached to Prog is
highlighted in green. B. Molecular dynamic simulation of PP-5 peptide (solid line) and GSG-10 peptide (dotted line). The distance from the ﬁrst peptide bond to the last over
simulation time is plotted. Dashed line represents the distance for the “perfect” helix for both peptides. C. Molecular dynamics simulation of PP-5 associated with a POPC
membrane. Blue spheres represent the head groups of phospholipids. Color scheme for the proline residues is the same as above.
Fig. 3. In vitro cholesterol efﬂux assay. Cholesterol efﬂux from ABCA1-BHK cells to peptides at the indicated concentration on the X-axis plotted, using a logarithmic scale. Results
are expressed as the mean ± 1 SD of triplicates. N.D. (not determined).
D.O. Sviridov et al. / Biochemical and Biophysical Research Communications 471 (2016) 560e565 563peptide, the polypro peptides, particularly the longer ones (PP-3,
PP-4, PP-5), caused HDL remodeling and the formation of small pre-
b like HDL of approximately 7 nM in diameter (Fig. 4A). At the 1 uM
dose, the effect of the addition of PP-3, PP-4 and PP-5 on increasingcholesterol efﬂux to serum from ABCA1 expressing BHK cells was
similar to the 5A peptide (Fig. 4B).
Fig. 4. HDL remodeling. A. HDL size subfracation analysis after native PAGE before and after addition of 1 uM peptides. Antibodies against human ApoA-I in conjugation with HRP
were used to visualize subclass size distribution. B. In vitro cholesterol efﬂux assay using LDL-depleted human pooled plasma before (grey column) and after addition of either 0.1
uM (white columns) or 1 uM (black columns) peptides. Results are expressed as the mean ± 1 SD of triplicates. * indicates (P < 0.05) compared to control.
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The ABCA1 transporter is induced in cholesterol loaded cells,
such as those in atherosclerotic plaques, and promotes the efﬂux of
excess cellular cholesterol to HDL [7,8]. The exact molecular
mechanism for cholesterol efﬂux is still not fully understood, but it
is thought that ABCA1 ﬂips phospholipids to the outer membrane
leaﬂet and creates small membrane microdomains that form out-
ward evaginations [20]. It has been shown that apoA-I, the main
protein component of HDL, particularly when in a relatively lipid
poor state, such as pre-b HDL, can bind to these lipid microdomains
and solubilize them, thereby releasing cholesterol and forming
larger HDL subspecies. This is thought to occur by a detergent-like
extraction process, whereby the amphipathic helices of apoA-I
insert into the lipid microdomain created by ABCA1 and then
later reorganizes to stabilize the nascent discoidal shaped HDL
particle that forms by this process [20].
ApoA-I has 10 amphipathic helices, but small synthetic peptides
containing only a few or even one amphipathic a helix can also
promote cholesterol efﬂux by the ABCA1 transporter [21]. These
peptides can bemadewith either L or D amino acids, indicating that
this is not a stereoselective process and that either right-handed or
left-handed amphipathic a-helices can promote cholesterol efﬂux
[22]. The same peptides, however, made with a mixture of L and D
amino acids, which interfere with backbone hydrogen bonding and
do not form a helix, are inactive [22]. Amphipathic peptides that
efﬂux cholesterol are typically at least 18 residues or longer,
because much shorter peptides cannot form stable helices. Adding
salt bridges [2] or hydrocarbon staples [23] to stabilize helix for-
mation has been shown to increase the ability of these peptides to
efﬂux cholesterol by ABCA1.
In this study, we show that an amphipathic polypro helical
peptide as short as 9 amino acids, PP-3, was comparable in
cholesterol efﬂux to the much longer 5A peptide containing 37
amino acids. The PP-4 peptide containing 4 trimeric repeats (12
amino acids) had an apparent Km that was approximately 20-fold
lower in molar units than the 5A peptide. Interestingly, PP-5,
which by CD spectroscopy had the most polypro type-II helical
content (Fig. 2C), was less effective in cholesterol efﬂux than PP-4. It
may be that this peptide has exceeded the optimum length for
cholesterol efﬂux by ABCA1.When in a perfect helical conformation
PP-5 would be expected to have a peptide length of 46.5 Å, which is
considerably longer than the predicted length of the typical a-helix
found on ApoA-I, which has 18 residues and is about 27 Å in length.
It may be that when an amphipathic peptide is too long, it is lesseffective in solubilizing the lipid domain created by ABCA1 and or
cannot as readily stabilize the nascent HDL particle structure,
particularly if it is inﬂexible. Similarly, peptides that are too short,
such as PP-2, may also be less efﬁcient in both of these processes
and or may have too low of an afﬁnity for lipid. Although the
dihedral angles of polypro peptides are constrained, it has been
shown that polypro peptides containing 6 or less residues do not
form stable helices [24,25], and thus short polypro peptides would
be expected to have less lipid afﬁnity. When added to plasma the
polypro peptides were similar in potency to 5A in stimulating
cholesterol efﬂux by ABCA1 (Fig. 4). This suggests that although
they are more potent when tested by themselves (Fig. 3), polypro
peptides are comparable to 5A in causing the remodeling of
endogenous HDL and the formation of pre-b HDL (Fig. 4), which is
the primary HDL particle in plasma that causes ABCA1-dependent
cholesterol efﬂux.
Like the polypro peptides in this study, the hydrophobic face of
apoA-I mimetic peptides are often designed to have phenylalanine
residues because of the high lipid afﬁnity of the phenyl side chains.
The polar face of apoA-I mimetic peptides like the full length apoA-I
protein typically have a mixture of positively and negatively
charged amino acids and formwhat are called Type A amphipathic
a-helices [26]. Because ionic interactions between charged groups
on peptides with either the charged head groups of lipids or
charged groups on other membrane proteins has been proposed to
contribute to the cytotoxicity [19,27], we instead used polar sugars
on the hydrophilic face of our polypro peptides. Despite the high
potency of polypro peptides in promoting cholesterol efﬂux, they
did not cause non-speciﬁc cholesterol efﬂux from control cells not
expressing ABCA1 (Supplement Fig. 1), which typically occurs with
non-speciﬁc and cytotoxic apoA-I mimetic peptides [19]. They also
showed no signs of cytotoxicity on red blood cells (Supplement
Fig. 2), which are very susceptible to any type of cell membrane
damage. This may be analogous to the situation of how low mo-
lecular weight detergentsmadewith sugars, such as octylglucoside,
are less membrane damaging and preserve membrane protein
function better than ionic detergents, such as sodium dodecyl
sulfate [28,29]. Any type of polar sugar would probably sufﬁce for
making the polypro amphipathic peptides, although different type
of sugars could possibly be chosen to target speciﬁc cells for
cholesterol efﬂux, such as mannose for targeting the mannose re-
ceptor on macrophages [30]. In this study, we chose to use N-acetyl
glucosamine to potentially target the asialoglycoprotein receptor
for facilitating hepatic uptake [31], which is the usual ﬁnal fate of
cholesterol that is removed by HDL.
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